Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 77.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 270,523 shares of the company's stock after selling 945,399 shares during the quarter. Assenagon Asset Management S.A. owned 0.60% of Cardiff Oncology worth $722,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRDF. Callan Capital LLC grew its position in Cardiff Oncology by 37.2% during the first quarter. Callan Capital LLC now owns 42,747 shares of the company's stock worth $228,000 after buying an additional 11,600 shares during the period. Blair William & Co. IL grew its position in shares of Cardiff Oncology by 32.4% in the first quarter. Blair William & Co. IL now owns 172,180 shares of the company's stock valued at $919,000 after purchasing an additional 42,180 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Cardiff Oncology by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company's stock valued at $10,260,000 after purchasing an additional 9,468 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $256,000. Finally, Rhumbline Advisers acquired a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $102,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Stock Up 2.7 %

Shares of CRDF traded up $0.08 on Friday, hitting $3.21. 683,914 shares of the stock traded hands, compared to its average volume of 720,176. The firm has a market capitalization of $149.19 million, a P/E ratio of -3.52 and a beta of 1.93. The stock's 50 day moving average is $2.61 and its two-hundred day moving average is $2.78. Cardiff Oncology, Inc. has a 1 year low of $0.94 and a 1 year high of $6.42.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.12 million. Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. During the same period in the previous year, the company posted ($0.25) EPS. Research analysts forecast that Cardiff Oncology, Inc. will post -1 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on shares of Cardiff Oncology in a research report on Friday, September 6th. They issued a "buy" rating and a $8.00 price target on the stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.